CARB-X Provides Funding to AdJane for Gonorrhea Vaccine Development Initiative
In a significant push towards combating infectious diseases, CARB-X (the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has announced a funding grant of $2.6 million to AdJane, a clinical-stage vaccine development company based in the Netherlands. This funding is designated for the advancement of AdJane's innovative candidate vaccine aimed at preventing infections caused by Neisseria gonorrhoeae, the bacterium responsible for gonorrhea, one of the most prevalent sexually transmitted infections (STIs) globally.
Gonorrhea leads to over 80 million new infections each year, which can result in serious complications like pelvic inflammatory disease, infertility, and increased susceptibility to HIV. Despite its high incidence, many cases go undiagnosed due to a lack of symptoms. Moreover, Neisseria gonorrhoeae fails to induce durable natural immunity, resulting in frequent reinfections, complex treatment protocols, and heightened exposure to antibiotics—factors that contribute to rising antimicrobial resistance.
Richard Alm, interim head of R&D at CARB-X, emphasized the urgency of developing effective solutions as clinical management of gonorrhea becomes increasingly intricate due to growing antibiotic resistance and limited treatment options. He announced, "AdJane's approach represents a technically innovative strategy to tackle key challenges such as creating protective immunity, reducing gonorrhea infection rates, and curbing the spread of antimicrobial resistance."
AdJane leverages its proprietary native Outer Membrane Vesicle (nOMV) platform for vaccine development. Their approach employs a heterologous strategy designed to generate a broad-spectrum immune response by targeting highly conserved gonococcal antigens. This method is anticipated to produce a candidate vaccine that not only provokes a specific immune response but also enhances overall protection against Neisseria gonorrhoeae.
Anita Gashi, CEO of AdJane, expressed her enthusiasm about joining CARB-X's portfolio, stating, "We appreciate the support as we work towards our goal of addressing antimicrobial resistance with our platform. This award highlights the promise of our cutting-edge nOMV platform in tackling global health issues like gonorrhea. Our heterologous approach aims to create a single-component vaccine that provides both broad and specific immunological protection, facilitating both development and manufacturing processes."
This recent funding marks a continuation of support from CARB-X, which previously invested in the development of AdJane’s gonorrhea vaccine. Since its launch in 2016, CARB-X has been instrumental in revitalizing the early-stage antibiotic development landscape, having funded 123 R&D projects across 14 countries, with notable achievements including 25 projects progressing to or completing clinical trials, and three products reaching the market. Additionally, at least ten developers with active R&D initiatives have established advanced development partnerships that may aid their clinical development post-CARB-X.
All CARB-X-funded product developers must comply with contractual obligations promoting responsible management and appropriate access, especially within low- and middle-income countries. Funding for CARB-X is partially sourced from the U.S. Department of Health and Human Services (HHS) and various other international organizations and foundations.
As challenges from antibiotic-resistant bacteria continue to escalate, initiatives like the one undertaken by AdJane become all the more critical. AdJane’s long-standing development of their nOMV platform has been supported by leading Dutch governmental research institutions, allowing for rapid vaccine advancement through diverse implementation modalities. Their innovative platform not only targets preventive applications but is also equipped for therapeutic uses.
In the fight against antimicrobial resistance and infectious diseases, the collaborative effort between CARB-X and AdJane exemplifies a forward-thinking approach to global public health challenges. The concerted focus on gonorrhea, a condition often overlooked in mainstream health discussions, underscores the necessity of innovative solutions to prevent and manage STIs effectively.
For more details about CARB-X and its projects, visit CARB-X's official website, and for specific information about AdJane, you can explore their initiatives at AdJane's website.
Gonorrhea leads to over 80 million new infections each year, which can result in serious complications like pelvic inflammatory disease, infertility, and increased susceptibility to HIV. Despite its high incidence, many cases go undiagnosed due to a lack of symptoms. Moreover, Neisseria gonorrhoeae fails to induce durable natural immunity, resulting in frequent reinfections, complex treatment protocols, and heightened exposure to antibiotics—factors that contribute to rising antimicrobial resistance.
Richard Alm, interim head of R&D at CARB-X, emphasized the urgency of developing effective solutions as clinical management of gonorrhea becomes increasingly intricate due to growing antibiotic resistance and limited treatment options. He announced, "AdJane's approach represents a technically innovative strategy to tackle key challenges such as creating protective immunity, reducing gonorrhea infection rates, and curbing the spread of antimicrobial resistance."
AdJane leverages its proprietary native Outer Membrane Vesicle (nOMV) platform for vaccine development. Their approach employs a heterologous strategy designed to generate a broad-spectrum immune response by targeting highly conserved gonococcal antigens. This method is anticipated to produce a candidate vaccine that not only provokes a specific immune response but also enhances overall protection against Neisseria gonorrhoeae.
Anita Gashi, CEO of AdJane, expressed her enthusiasm about joining CARB-X's portfolio, stating, "We appreciate the support as we work towards our goal of addressing antimicrobial resistance with our platform. This award highlights the promise of our cutting-edge nOMV platform in tackling global health issues like gonorrhea. Our heterologous approach aims to create a single-component vaccine that provides both broad and specific immunological protection, facilitating both development and manufacturing processes."
This recent funding marks a continuation of support from CARB-X, which previously invested in the development of AdJane’s gonorrhea vaccine. Since its launch in 2016, CARB-X has been instrumental in revitalizing the early-stage antibiotic development landscape, having funded 123 R&D projects across 14 countries, with notable achievements including 25 projects progressing to or completing clinical trials, and three products reaching the market. Additionally, at least ten developers with active R&D initiatives have established advanced development partnerships that may aid their clinical development post-CARB-X.
All CARB-X-funded product developers must comply with contractual obligations promoting responsible management and appropriate access, especially within low- and middle-income countries. Funding for CARB-X is partially sourced from the U.S. Department of Health and Human Services (HHS) and various other international organizations and foundations.
As challenges from antibiotic-resistant bacteria continue to escalate, initiatives like the one undertaken by AdJane become all the more critical. AdJane’s long-standing development of their nOMV platform has been supported by leading Dutch governmental research institutions, allowing for rapid vaccine advancement through diverse implementation modalities. Their innovative platform not only targets preventive applications but is also equipped for therapeutic uses.
In the fight against antimicrobial resistance and infectious diseases, the collaborative effort between CARB-X and AdJane exemplifies a forward-thinking approach to global public health challenges. The concerted focus on gonorrhea, a condition often overlooked in mainstream health discussions, underscores the necessity of innovative solutions to prevent and manage STIs effectively.
For more details about CARB-X and its projects, visit CARB-X's official website, and for specific information about AdJane, you can explore their initiatives at AdJane's website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.